All News
Filter News
Found 808,623 articles
-
Potential Cure For HIV Successfully Completes Pre-investigational New Drug (Pre-Ind) Stage Of FDA Approval Process
10/19/2021
A potential cure for HIV, developed by pioneering research scientist Dr. Serhat Gumrukçu, Director of the Seraph Research Institute (SRI), and his team have successfully completed the Pre-Investigational New Drug (IND) process for the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER).
-
AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
10/19/2021
AVROBIO, Inc. today reported new safety data from the first lentiviral gene therapy clinical trials for Fabry disease and Gaucher disease, as well as new high-resolution cellular data providing insights into the mechanisms of action of its gene therapies.
-
Neuronetics Launches Upgrades of NeuroStar® Advanced Therapy for Mental Health
10/19/2021
Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from neurohealth disorders announced today the release of the latest evolution of their NeuroStar® Advanced Therapy system with upgraded equipment and features.
-
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
10/19/2021
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that the company entered into an agreement with Beam Therapeutics Inc. (NASDAQ: BEAM) for non-exclusive commercial rights to Beam’s CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs.
-
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter 2021 Financial Results and Operational Highlights
10/19/2021
Oncolytics Biotech® Inc. announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021.
-
Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)
10/19/2021
Dr. Reddy’s Laboratories Ltd. announced the final approval of its Abbreviated New Drug Application for Lenalidomide Capsules, in 2.5 mg and 20 mg strengths, and tentative approval for 5 mg, 10 mg, 15 mg, and 25 mg strengths, a therapeutic equivalent generic version of REVLIMID® Capsules, from the U.S. Food and Drug Administration.
-
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
10/19/2021
NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced that its liquid biopsy focused subsidiary Inivata Limited has entered into a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada, for the use of Inivata's liquid biopsy assays, InVisionFirst®-Lung and RaDaR™ in two separate studies.
-
Gladstone Neuroscience Researcher Elected to the National Academy of Medicine
10/19/2021
Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease and senior investigator at Gladstone Institutes, has been elected to the National Academy of Medicine.
-
West Introduces DeltaCube™ Modeling Platform and NovaGuard® SA Pro Safety System for 0.5 mL Standard Glass Syringes at Interphex
10/19/2021
West Pharmaceutical Services, Inc. announced that it will unveil its DeltaCube™ Modeling Platform as well as the new NovaGuard® SA Pro Safety System for ISO 0.5mL Standard Glass Syringes at Interphex, taking place October 19 to 21 in New York, New York.
-
Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
10/19/2021
Aadi Bioscience, Inc. announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., will present at H.C. Wainwright’s 2nd Annual Precision Oncology Conference, which will be held virtually.
-
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
10/19/2021
Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, announced an expansion of the clinical development program for the Company's lead asset, ATH434, in patients with Multiple System Atrophy, a rare and rapidly progressing Parkinsonian disorder.
-
Maintaining Balance in the Brain
10/19/2021
Gladstone scientists help explain how reducing the protein tau can prevent abnormal brain activity associated with Alzheimer's disease, autism, and epilepsy
-
American Lung Association Increases Research Investment; Funds $12.6 Million in Lung Health Grants
10/19/2021
At a time when lung health is more important than ever, the American Lung Association announced that it has increased its research funding to award $12.6 million for more than 100 research grants.
-
FDA Issues Landmark Proposal to Improve Access to Hearing Aid Technology for Millions of Americans
10/19/2021
Tthe U.S. Food and Drug Administration issued a landmark proposal intended to improve access to and reduce the cost of hearing aid technology for millions of Americans.
-
X4 Pharmaceuticals Expands Commercial Leadership Expertise with Appointment of Françoise de Craecker to Board of Directors and Karolyn Park as Vice President, U.S. Commercial
10/19/2021
X4 Pharmaceuticals, Inc. announced the appointment of Françoise de Craecker to the company’s Board of Directors and the recent hiring of Karolyn Park to the newly created role of Vice President, U.S. Commercial, significantly strengthening the company’s depth and breadth of commercial leadership experience.
-
Intuitive Announces Executive Leadership Changes
10/19/2021
Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced executive leadership changes that reflect the company’s growth and plans for advancing minimally invasive care globally.
-
Intuitive Announces Third Quarter 2021 Earnings
10/19/2021
Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced financial results for the quarter ended September 30, 2021.
-
Versantis Appoints Leading Hepatologist Prof Dr Katharina Staufer as Chief Medical Officer
10/19/2021
Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, announced the appointment of Prof Dr Katharina Staufer as Chief Medical Officer.
-
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
10/19/2021
Opthea Limited, a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that the first clinical trial sites in the Asia-Pacific region are now open for patient enrollment into the OPT-302 Phase 3 pivotal clinical program for the treatment of wet age-related macular degeneration.
-
Syneos Health Schedules Third Quarter 2021 Earnings Call for Wednesday, November 3rd, 2021
10/19/2021
Syneos Health®, the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2021 financial results on Wednesday, November 3rd, 2021, prior to its earnings call at 8:00 a.m. ET.